{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T02:41:00Z","timestamp":1791168060785,"version":"4.1.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2012,2,22]],"date-time":"2012-02-22T00:00:00Z","timestamp":1329868800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr HIV\/AIDS Rep"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1007\/s11904-012-0111-2","type":"journal-article","created":{"date-parts":[[2012,2,21]],"date-time":"2012-02-21T07:23:40Z","timestamp":1329809020000},"page":"132-138","source":"Crossref","is-referenced-by-count":3,"title":["Antiviral Drugs and the Treatment of Hepatitis C"],"prefix":"10.1007","volume":"9","author":[{"given":"Ziba","family":"Jalali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen K.","family":"Rockstroh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,2,22]]},"reference":[{"key":"111_CR1","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents, Guidelines for the use of antiretroviral agents in HIV-1-infected adults and Adolescents. Department of Health and Human Services. 2009. p. 1\u2013161. http:\/\/www.aidsinfo.nih.gov\/contentfiles\/AdultandAdolescentGL001419.pdf ."},{"key":"111_CR2","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/S0140-6736(10)62001-6","volume":"377","author":"D Joshi","year":"2011","unstructured":"Joshi D, O\u2019Grady J, Dietrich D, et al. Increasing burden of liver disease in patients with HIV infection. Lancet. 2011;377:1198\u2013209.","journal-title":"Lancet"},{"key":"111_CR3","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1468-1293.2007.00535.x","volume":"9","author":"J Rockstroh","year":"2008","unstructured":"Rockstroh J, Bhagani S, Benhamou Y, et al. European AIDS Clinical (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med. 2008;9:82\u20138.","journal-title":"HIV Med"},{"key":"111_CR4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1468-1293.2009.00781.x","volume":"11","author":"G Brook","year":"2010","unstructured":"Brook G, Main J, Nelson MA, et al. British HIV Association guidelines for the management of coinfection with HIV-1 and hepatitis B or C Virus. HIV Med. 2010;11:1\u201330.","journal-title":"HIV Med"},{"key":"111_CR5","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa040842","volume":"351","author":"FJ Torriani","year":"2004","unstructured":"Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004;351:438\u201350.","journal-title":"N Engl J Med."},{"key":"111_CR6","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1001\/jama.292.23.2839","volume":"292","author":"F Carrat","year":"2004","unstructured":"Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA. 2004;292:2839\u201348.","journal-title":"JAMA."},{"key":"111_CR7","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/hep.22598","volume":"49","author":"M Laguno","year":"2009","unstructured":"Laguno M, Cifuentes C, Murillas J, et al. Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients. Hepatology. 2009;49:22\u201331.","journal-title":"Hepatology"},{"key":"111_CR8","doi-asserted-by":"crossref","unstructured":"Nunez M, Miralles C, Berdun MA et al for the PRESCO study group. Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: The PRESCO trial. AIDS Res Hum Retrovir 2007;23:972\u201382.","DOI":"10.1089\/aid.2007.0011"},{"key":"111_CR9","doi-asserted-by":"crossref","unstructured":"Rodriguez-Torres M, Slim J, Bhatti L, et al. On behalf of the PARADIGM Study Investigators: Peginterferon alfa-2A (40KD) plus 800 or 1000\/1200\u00a0mg\/day RBV in G1 HIV-HCV-Co-infection patients: early responses to treatment and predictability for SVR in PARADIGM study. Presented at the European Association for the Study of the Liver (EASL). Vienna, Austria, March 30\u2013April 3, 2010.","DOI":"10.1016\/S0168-8278(10)60298-X"},{"key":"111_CR10","first-page":"2563","volume":"91","author":"JK Rockstroh","year":"1996","unstructured":"Rockstroh JK, Spengler U, Sudhop T, et al. Immunosuppression may lead to progression of hepatitis-C-virus (HCV) associated liver disease in HIV-HCV coinfected hemophiliacs. Am J Gastroenterol. 1996;91:2563\u20138.","journal-title":"Am J Gastroenterol"},{"key":"111_CR11","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1016\/S0140-6736(03)14844-1","volume":"362","author":"N Qurishi","year":"2003","unstructured":"Qurishi N, Kreuzberg C, L\u00fcchters G, et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C coinfection. Lancet. 2003;362:1708\u201313.","journal-title":"Lancet"},{"key":"111_CR12","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jhep.2005.07.006","volume":"44","author":"N Br\u00e4u","year":"2006","unstructured":"Br\u00e4u N, Salvatore M, R\u00edos-Bedoya CF, et al. Slower fibrosis progression in HIV\/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol. 2006;44:47\u201355.","journal-title":"J Hepatol"},{"key":"111_CR13","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/QAI.0b013e31815ac47d","volume":"47","author":"M Opravil","year":"2008","unstructured":"Opravil M, Sasadeusz J, Cooper DA, et al. Effect of baseline CD4 cell count on the efficacy and safety of peg-interferon-alpha 2a (40 KD)\u2009+\u2009ribavirin in patients with HIV\/hepatitis C virus coinfection. J Acquir Immune Def Syndr. 2008;47:36\u201349.","journal-title":"J Acquir Immune Def Syndr"},{"key":"111_CR14","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1136\/bmj.322.7299.1410","volume":"322","author":"IV Weller","year":"2001","unstructured":"Weller IV, Williams IG. ABC of AIDS. Antiretroviral drugs. BMJ. 2001;322:1410\u20132.","journal-title":"BMJ."},{"key":"111_CR15","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/j.1365-2893.2006.00749.x","volume":"13","author":"D Alvarez","year":"2006","unstructured":"Alvarez D, Dieterich DT, Brau N, et al. Zidovudine use but not weight-based ribavirin dosing impacts anemia during HCV treatment in HIV infected persons. J viral Hepat. 2006;13:683\u20139.","journal-title":"J viral Hepat"},{"key":"111_CR16","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1093\/jac\/dkr362","volume":"66","author":"J Berenguer","year":"2011","unstructured":"\u2022 Berenguer J, von Wichmann MA, Quereda C, et al. On behalf of the GESIDA 36\/03 and 50\/06 Study Groups.: Effect of accompanying antiretroviral drugs on virological response to pegylated interferon and ribavirin in patients co-infected with HIV and hepatitis C virus. J Antimicrob Chemother. 2011;66:2843\u20139. Largest pooled analyses of HIV\/HCV co-infected patients undergoing PEG-IFN\/RBV therapy to date and evaluation of various NRTI backbones and their potential impact on SVR rates under HCV therapy.","journal-title":"J Antimicrob Chemother"},{"key":"111_CR17","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1111\/j.1365-2036.2010.04269.x","volume":"31","author":"R MacNicholas","year":"2010","unstructured":"MacNicholas R, Norris S. Optimizing SVR and management of the haematological side effects of peginterferon\/ribavirin antiviral therapy for HCV\u2014the role of epoetin, G-CSF and novel agents. Aliment Pharmacol Ther. 2010;31:929\u201337.","journal-title":"Aliment Pharmacol Ther"},{"key":"111_CR18","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1086\/515398","volume":"44","author":"CM Behler","year":"2007","unstructured":"Behler CM, Vittinghoff E, Lin F, et al. Hematological toxicity associated with interferon-based hepatitis C therapy in HIV type 1 coinfected patients. Clin Infect Dis. 2007;44:1375\u201383.","journal-title":"Clin Infect Dis"},{"key":"111_CR19","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1177\/135965350701200805","volume":"12","author":"J Mira","year":"2007","unstructured":"Mira J, Lopes-Cortes LF, Merino D, et al. Predictors of severe hematological toxicity secondary to pegylated interferon plus ribavirin treatment. Antiviral Ther. 2007;12:1225\u201335.","journal-title":"Antiviral Ther"},{"key":"111_CR20","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/S0140-6736(00)03618-7","volume":"357","author":"A Lafeuillade","year":"2001","unstructured":"Lafeuillade A, Hittinger G, Chadapaud S. Increased mitochondrial toxicity with ribavirin in HIV\/HCV coinfection. Lancet. 2001;357:280\u20131.","journal-title":"Lancet"},{"key":"111_CR21","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1086\/653214","volume":"202","author":"T Reiberger","year":"2010","unstructured":"Reiberger T, Kosi L, Maresch J, et al. Mitochondrial toxicity is associated with virological response in patients with HIV and hepatitis C virus coinfection treated with ribavirin and highly active antiretroviral therapy. J Infect Dis. 2010;202:156\u201360.","journal-title":"J Infect Dis"},{"key":"111_CR22","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1086\/527565","volume":"46","author":"F Bani-Sadr","year":"2008","unstructured":"Bani-Sadr F, Lapidus N, Bedossa P, et al. French National Agency for Research on AIDS. Viral Hepatitis-HC02-Ribavic Study Team.: Progression of fibrosis in HIV and hepatitis C virus-coinfected patients treated with interferon plus ribavirin-based therapy: analysis of risk factors. Clin Infect Dis. 2008;46:768\u201374.","journal-title":"Clin Infect Dis"},{"key":"111_CR23","first-page":"344","volume":"13","author":"AA Butt","year":"2003","unstructured":"Butt AA. Fatal lactic acidosis and pancreatitis associated with ribavirin and didanosine therapy. AIDS Read. 2003;13:344\u20138.","journal-title":"AIDS Read."},{"key":"111_CR24","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/00002030-200409030-00002","volume":"18","author":"S Mauss","year":"2004","unstructured":"Mauss S, Valenti W, De Pamphillis J, et al. Risk factors for hepatic decompensation in patients with HIV\u2013HCV co-infection and liver cirrhosis during interferon-based therapy. AIDS. 2004;18:21\u20135.","journal-title":"AIDS"},{"key":"111_CR25","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jhep.2005.11.025","volume":"44","author":"C Perronne","year":"2006","unstructured":"Perronne C. Antiviral Hepatitis and antiretroviral drug interactions. J Hepatol. 2006;44:119\u201325.","journal-title":"J Hepatol"},{"key":"111_CR26","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1086\/313912","volume":"31","author":"JT Lonergan","year":"2000","unstructured":"Lonergan JT, Behling C, Pfander H, et al. Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens. Clin Infect Dis. 2000;31:162\u20136.","journal-title":"Clin Infect Dis"},{"key":"111_CR27","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1365-2893.2007.00939.x","volume":"15","author":"Bani-Sadr","year":"2008","unstructured":"Bani-Sadr, Lapidus N, Melchior JC, et al. Severe weight loss in HIV\/HCV co-infected patients treated with interferon plus ribavirin: incidence and risk factors. J Viral Hepat. 2008;15:255\u201360.","journal-title":"J Viral Hepat"},{"key":"111_CR28","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/QAI.0b013e31802f12d3","volume":"44","author":"V Lo Re 3rd","year":"2007","unstructured":"Lo Re 3rd V, Kostman JR, Gross R, et al. Incidence and risk factors for weight loss during dual HIV\/Hepatitis therapy. Acquire Immune Defic Syndr. 2007;44:344\u201350.","journal-title":"Acquire Immune Defic Syndr"},{"key":"111_CR29","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/QAI.0b013e318040b2b6","volume":"45","author":"F Bani-Sadr","year":"2007","unstructured":"Bani-Sadr F, Denoeud L, Morand P, et al. Early virologic failure in HIV-coinfected hepatitis C patients treated with peg-IFN-RBV combination: does abacavir play a role? J Acquir Immune Defic Syndr. 2007;45:123\u20135.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"111_CR30","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1177\/135965350801300303","volume":"13","author":"E Vispo","year":"2008","unstructured":"Vispo E, Barreiro P, Pineda J, et al. Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir. Antivir Ther. 2008;13:429\u201337.","journal-title":"Antivir Ther"},{"key":"111_CR31","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1177\/135965350801300709","volume":"13","author":"N Laufer","year":"2008","unstructured":"Laufer N, Laguno M, Perez I, et al. Abacavir does not influence the rate of virological response in HIV-HCV-coinfected patients treated with pegylated interferon and weight-adjusted ribavirin. Anitvir Ther. 2008;13:953\u20137.","journal-title":"Anitvir Ther"},{"key":"111_CR32","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3851\/IMP1492","volume":"15","author":"VK Amorosa","year":"2010","unstructured":"Amorosa VK, Slim J, Moinzer K, et al. The influence of abacavir and other antiretroviral agents on virological response to HCV therapy among antiretroviral-treated HIV-infected patients. Antivir Ther. 2010;15:91\u20139.","journal-title":"Antivir Ther"},{"key":"111_CR33","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1177\/135965350801300303","volume":"13","author":"E Vispo","year":"2008","unstructured":"Vispo E, Barreiro P, Pineda JA, et al. Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir. Antivir Ther. 2008;13:429\u201337.","journal-title":"Antivir Ther"},{"key":"111_CR34","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1056\/NEJMoa051871","volume":"354","author":"JE Gallant","year":"2006","unstructured":"Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med. 2006;354:251\u201360.","journal-title":"N Engl J Med"},{"key":"111_CR35","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/j.1468-1293.2009.00716.x","volume":"10","author":"CL Woodward","year":"2009","unstructured":"Woodward CL, Hall AM, Williams IG, et al. Tenofovir-associated renal and bone toxicity. HIV Med. 2009;10:482\u20137.","journal-title":"HIV Med"},{"key":"111_CR36","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1517\/14740331003627458","volume":"9","author":"S Rodriguez-Novoa","year":"2010","unstructured":"Rodriguez-Novoa S, Alvarez E, Labarga P, et al. Renal toxicity associated with tenofovir use. Expert Opin Drug Saf. 2010;9:545\u201359.","journal-title":"Expert Opin Drug Saf"},{"key":"111_CR37","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/QAI.0b013e31817bbeb9","volume":"49","author":"C Quereda","year":"2008","unstructured":"Quereda C, Corral I, Moreno A, et al. Effect of treatment with efavirenz on neuropsychiatric adverse events of interferon in HIV\/HCV co-infected patients. J Acquire Immune Defic Syndr. 2008;49:61\u20133.","journal-title":"J Acquire Immune Defic Syndr"},{"key":"111_CR38","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1097\/00002030-200403260-00007","volume":"18","author":"J Macias","year":"2004","unstructured":"Macias J, Castellano V, Merchante N, et al. Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: impact of nevirapine. AIDS. 2004;18:767\u201374.","journal-title":"AIDS"},{"key":"111_CR39","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S1542-3565(04)00129-6","volume":"2","author":"RK Sterling","year":"2004","unstructured":"Sterling RK, Wilson MS, Sanyal AJ, et al. Impact of highly active antiretroviral therapy on the spectrum of liver disease in HCV-HIV coinfection. Clin Gastroenterol Hepatol. 2004;2:432\u20139.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"111_CR40","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/hep.20541","volume":"41","author":"S Mehta","year":"2005","unstructured":"Mehta S, Thomas DL, Toberson M, et al. The effect of antiretroviral therapy on liver disease among adults with HIV and hepatitis C coinfection. Hepatology. 2005;41:123\u201331.","journal-title":"Hepatology"},{"key":"111_CR41","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1053\/jhep.2002.30319","volume":"35","author":"MS Sulkowski","year":"2002","unstructured":"Sulkowski MS, Thomas DL, Mehta SH, et al. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology. 2002;35:182\u20139.","journal-title":"Hepatology"},{"key":"111_CR42","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1053\/j.gastro.2010.11.052","volume":"140","author":"BH McGovern","year":"2011","unstructured":"McGovern BH. Hepatic steatosis in IHV\/HCV-coinfected patients: time to reevaluate! Gastroenterology. 2011;140:809\u201317.","journal-title":"Gastroenterology"},{"key":"111_CR43","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1053\/j.gastro.2010.11.052","volume":"140","author":"TA Woreta","year":"2011","unstructured":"\u2022 Woreta TA, Stucliffe CG, Mehta AH, et al. Incidence and risk factors for steatosis progression in adults coinfected with HIV and Hepatitis C virus. Gastroenterology. 2011;140:809\u201317. Prospective study on the natural history of steatosis in patients co-infected with HIV and HCV who attended an urban HIV clinic. Antiretroviral therapy and high counts of CD4(+) T cells were associated with reduced progression of steatosis in patients co-infected with HIV and HCV. Efforts to diagnose and prevent steatosis should focus on persons with a high body mass index and excessive alcohol intake.","journal-title":"Gastroenterology"},{"key":"111_CR44","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1097\/QAD.0b013e3283177f38","volume":"22","author":"S Rodr\u00edguez-N\u00f3voa","year":"2008","unstructured":"Rodr\u00edguez-N\u00f3voa S, Morello J, Gonz\u00e1lez M, et al. Increase in serum bilirubin in HIV\/hepatitis C virus-coinfected patients on atazanavir therapy following initiation of pegylated interferon and ribavirin. AIDS. 2008;22:2535\u20137.","journal-title":"AIDS"},{"key":"111_CR45","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1089\/aid.2006.0178","volume":"23","author":"JC Gathe Jr","year":"2007","unstructured":"Gathe Jr JC, Pierone G, Piliero P, et al. Efficacy and safety of three doses of tipranavir boosted with ritonavir in treatment-experienced HIV type-1 infected patients. AIDS Res Hum Retroviruses. 2007;23:216\u201323.","journal-title":"AIDS Res Hum Retroviruses"},{"key":"111_CR46","doi-asserted-by":"crossref","first-page":"G949","DOI":"10.1152\/ajpgi.00215.2003","volume":"285","author":"RF Schwabe","year":"2003","unstructured":"Schwabe RF, Bataller R, Brenner DA. Human hepatic stellate cells express CCR5 and RANTES to induce proliferation and migration. Am J Physiol Gastrointest Liver Physiol. 2003;285:G949\u2013958.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"111_CR47","first-page":"1858","volume":"119","author":"E Seki","year":"2009","unstructured":"Seki E, De Minicis S, Gwak GY, et al. CCR1 and CCR5 promote hepatic fibrosis in mice. J Clin Invest. 2009;119:1858\u201370.","journal-title":"J Clin Invest"},{"key":"111_CR48","doi-asserted-by":"crossref","first-page":"4721","DOI":"10.1128\/AAC.49.11.4721-4732.2005","volume":"49","author":"P Dorr","year":"2005","unstructured":"Dorr P, Westby M, Dobbs S, et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother. 2005;49:4721\u201332.","journal-title":"Antimicrob Agents Chemother"},{"key":"111_CR49","unstructured":"Nasta P, Gatti F, Borghi F, et al. Liver stiffness (LS) change in HIV-Hepatitis C (HCV) coinfected patients treated with CCR5 inhibitor based antiretroviral therapy. [abstract H3-810]. Presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Chicago, USA; September 17\u201320, 2011."},{"key":"111_CR50","unstructured":"Sulkowski M, Dietrich D, Sherman K, et al. Interim analysis of a phase 2a double-blind study of TVR in combination with pegIFN-a2a and RBV in HIV\/HCV co-infected patients [abstract 146LB]. Presented at the 18th conference on Retroviruses and Opportunistic Infections (CROI). Boston, USA; February 27\u2013March 2, 2011."},{"key":"111_CR51","unstructured":"Sherman KE, Rockstroh JK Dieterich, DT, et al. Telaprevir Combination with Peginterferon Alfa-2a\/Ribavirin in HCV\/HIV Coinfected Patients: 24-Week Treatment Interim Analysis. [abstract LB-8]. Presented at the 62nd Annual Meeting of the American Association for the Study of Liver Disease (AASLD). San Francisco, USA; November 4\u20138, 2011."},{"key":"111_CR52","unstructured":"Sulkowski M, Pol S, Cooper C, et al. Boceprevir plus peginterferon\/ribavirin for the treatment of HCV\/HIV co-infected patients: interim on-treatment results. [abstract LB-37]. Presented at the 49th Annual Meeting of the Infectious Diseases Society of America (IDSA); Boston, USA; October 20\u201323, 2011."},{"key":"111_CR53","unstructured":"\u2022\u2022 Kasserra C, Hughes, E, Treitel M, et al. Clinical pharmacology of BOC: metabolism, excretion and drug-drug interactions. [abstract 118]. 18th Conference on Retroviruses and Opportunistic Infections (CROI). Boston, USA; February 27\u2013March 2, 2011. The first public data studying boceprevir pharmacology which provided valuable information for prescribers."},{"key":"111_CR54","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","volume":"364","author":"BR Bacon","year":"2011","unstructured":"Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1207\u201317.","journal-title":"N Engl J Med"},{"key":"111_CR55","unstructured":"\u2022\u2022 Van Heeswijk RV, Boogaerts G, De Paepe E, et al. Pharmacokinetic interactions between ARV agents and the investigational HCV protease inhibitor TVR in healthy volunteers. [abstract 119]. 18th conference on Retroviruses and Opportunistic Infections (CROI). Boston, USA; February 27\u2013March 2, 2011. The first public data studying telaprevir drug interaction with antiretroviral drugs."},{"key":"111_CR56","unstructured":"Van Heeswijk R, Gysen V, Boogaerts G, et al. The pharmacokinetic interaction between tenofovir disoproxil fumarate and the investigational HCV protease inhibitor telaprevir. [abstract 966]. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). San Francisco, USA; September 13\u201317, 2008."},{"key":"111_CR57","unstructured":"Van Heeswijk R, Garg V, Boogaerts G, et al. The pharmacokinetic interaction between telaprevir and raltegravir in healthy volunteers. [abstract A1-1738a]. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Chicago, USA; September 17\u201320, 2011."}],"container-title":["Current HIV\/AIDS Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11904-012-0111-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11904-012-0111-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11904-012-0111-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,20]],"date-time":"2024-04-20T04:02:58Z","timestamp":1713585778000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11904-012-0111-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2,22]]},"references-count":57,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["111"],"URL":"https:\/\/doi.org\/10.1007\/s11904-012-0111-2","relation":{},"ISSN":["1548-3568","1548-3576"],"issn-type":[{"value":"1548-3568","type":"print"},{"value":"1548-3576","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2,22]]}}}